- Home
- LXEH vs COEP Comparison
LXEH vs COEP Comparison
Compare LXEH & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | COEP |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | China | United States |
| Employees | 192 | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 100.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXEH | COEP |
|---|---|---|
| Price | $0.32 | $15.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 236.5K | 74.3K |
| Earning Date | 12-30-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,585,942.00 | $500,996.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $2.31 |
| 52 Week High | $50.08 | $21.41 |
Technical Indicators
Market Signals| Indicator | LXEH | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 30.81 | 47.72 |
| Support Level | $0.31 | $15.40 |
| Resistance Level | $0.37 | $16.80 |
| Average True Range (ATR) | 0.03 | 1.57 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 18.36 | 20.64 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.